On January 3, Dongfulong rose 5% intraday, and as of 10:01, it was quoted at 24.
92 yuan, with a transaction of 126 million yuan and a turnover rate of 1.
19%.
The industry believes that the rapid rise of Dongfulong is mainly in the period
of new crown order digestion, international breakthrough, and new business cultivation.
Under the upgrading of pharmaceutical manufacturing, pharmaceutical machinery companies have set off a wave of fundraising and expansion
It is understood that in recent years, in order to improve the layout of the whole industrial chain, Dongfulong has continued to increase independent research and development, and has won a large number of orders, which has promoted the continuous growth
of performance.
Choice data shows that in the first three quarters of 2019-2022, the net profit of Dongfulong increased by 106.
95%, 217.
86%, 78.
59% and 8.
29%
respectively.
It is worth mentioning that it has also publicly stated that as of the first quarter of 2022, the company's order scale in hand has reached 8.
5 billion yuan, exceeding the annual revenue of 2021, in this context, the company's capacity gap has increased, and it is urgent to expand production capacity to meet the rapid growth of downstream market demand
.
On the evening of December 30, 2022, Dongfulong disclosed its fixed issuance report
.
This private placement is an important part of Dongfulong's accelerated expansion of production, and according to the announcement, the fixed increase will be mainly used to increase the production capacity of pharmaceutical equipment and supplement working capital
.
Among them, after deducting the issuance expenses, 530 million yuan will be used for the biopharmaceutical equipment industry trial production center project, 990 million yuan for the Jiangsu biomedical equipment industrialization base project, 1.
25 billion yuan for the Hangzhou life science industrialization base project, and 430 million yuan for supplementary working capital
.
For the company's fixed increase and expansion, the relevant person in charge has publicly stated that it is mainly based on the following judgment
.
First, in recent years, the discovery of new targets and the development of new targeted drugs have been accelerating, the number of clinical applications and approvals of targeted drugs has increased, and pharmaceutical companies need to purchase a large number of equipment to increase their production capacity
.
Second, the development of the biopharmaceutical industry has increased the demand
for high-level, high-quality medical equipment upstream.
In fact, under the background of medical insurance and centralized procurement policies on the manufacturing level and process control of domestic pharmaceutical companies, as well as the increasing demand for manufacturing upgrading, cost reduction and efficiency improvement of downstream pharmaceutical enterprises, in addition to Dongfulong, many pharmaceutical machinery companies have begun to make efforts to accelerate transformation and upgrading
by raising and expanding production.
For example, Chuangzhi Technology is committed to providing pharmaceutical companies with a full set of customized intelligent solutions in the field of pharmaceutical solid dosage forms
.
It updated its listing application review status
on December 12, 2022.
According to the prospectus disclosed and released by Chuangzhi Technology, the company intends to rush to IPO listing on the Growth Enterprise Market of the Shenzhen Stock Exchange, and intends to issue no more than 29,568,000 shares in the initial public offering (excluding the number of shares issued using the over-allotment option), and the new shares issued by the public account for no less than 25%
of the total share capital after this offering.
The proposed fundraising of 550 million yuan will be used for high-end pharmaceutical equipment industrialization construction projects, R&D center construction projects, and supplementary working capital
.
Prior to this, Chunguang Pharmaceutical Packaging has also officially landed on the Beijing Stock Exchange
.
According to the data, the main business of Chunguang Pharmaceutical is the research and development, production and sales
of food and pharmaceutical packaging equipment.
According to the announcement, its fundraising is also intended to be used for the construction of intelligent automation equipment production base projects
.
On the whole, in order to increase the development potential of production capacity construction and process technology, and improve brand and market share, innovation and upgrading are in full swing
.
The industry believes that in this context, domestic brand pharmaceutical equipment will rise rapidly, in the future, in addition to most subdivisions, in the high-end analytical instruments, some high-end reagents, specific membrane materials and other subdivisions may usher in more new breakthroughs, and accelerate the realization of import substitution
.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
